Abstract: OBJECTIVE To investigate the effect of atomization inhalation of pulmicort respulas in children with mycoplasma pulmonary infections. METHODS A total of 158 children with mycoplasma pneumonia were enrolled in our hospital from Feb. 2013 to Mar. 2017. They were randomly divided into observation group and control group (n = 79). Both groups received routine treatment, based on which the observation group received atomization inhalation of pulmicort respulas with continuous treatment for 7d. The fever time, lung rales disappearance time, cough disappearance time and chest pain returned to normal time of the two groups were recorded, and the lung function in children was detected. The main parameters included tidal volume (V-T), inspiratory midvio / expiratory flow velocity ratio (MTIF/MTEF), tidal peak expiratory flow rate (TEF25/PTEF), peak time ratio (t-PTEF / t-E), soluble intercellular adhesion molecule-1 (sICAM-1), insulin-like growth factor-1 (IGF-1) and pulmonary surfactant-associated protein A (SP-A) were detected, and the curative effects were evaluated. RESULTS The time of fever, the disappearance time of pulmonary rales, the disappearance time of cough and the time to recovery of chest radiograph in experimental group were all significantly lower than those in control group (P<0.05). After treatment, VT, TEF25/PTEF and t-PTEF/tE in experimental group were (12.86±1.58) ml/kg, (0.79±0.10)% and (46.32 ± 5.18)%, which were significantly higher than those in control group (P<0.05). After treatment, the levels of sICAM-1 (119.5±15.78) and SP-A (8.25±3.15) in experimental group were significantly lower than those in control group (P< 0.05). The serum IGF-1 level in experimental group was (178.35±18.95), which was significantly higher than that of control group (P<0.05). The efficacy of experimental group was significantly better than that of control group (P<0.05). CONCLUSION Pulmicort respulas in the treatment of mycoplasma pneumoniae can effectively regulate the levels of serum sICAM-1, IGF-1 and SP-A in children, improve the pulmonary function of children, and promote the improvement of clinical symptoms.